BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17301246)

  • 21. No association between fatty acid intake and adenomatous polyp recurrence in the polyp prevention trial.
    Cantwell MM; Forman MR; Albert PS; Snyder K; Schatzkin A; Lanza E;
    Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2059-60. PubMed ID: 16103463
    [No Abstract]   [Full Text] [Related]  

  • 22. Celecoxib: new indication. Ankylosing spondylitis: no pain justifies the use of a cox-2 inhibitor. Patients still exposed to unjustified risks.
    Prescrire Int; 2008 Jun; 17(95):106. PubMed ID: 18627117
    [No Abstract]   [Full Text] [Related]  

  • 23. Does the dose make the poison?
    Harris RE
    Science; 2005 Apr; 308(5719):203. PubMed ID: 15821073
    [No Abstract]   [Full Text] [Related]  

  • 24. The COX-2 story: is any drug completely "safe?".
    DuBois RN
    Gastroenterology; 2006 Jan; 130(1):6. PubMed ID: 16401461
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial.
    Meunier A; Lisander B; Good L
    Acta Orthop; 2007 Oct; 78(5):661-7. PubMed ID: 17966026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
    North GL
    Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Celecoxib and the CLASS study--worse and worse...].
    Slørdal L
    Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2219. PubMed ID: 12426903
    [No Abstract]   [Full Text] [Related]  

  • 28. Celecoxib-induced deep-vein thrombosis.
    Chan AL
    Ann Pharmacother; 2005 Jun; 39(6):1138. PubMed ID: 15840730
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
    Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
    Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Did targeted therapy fail cyclooxygenase too?
    Csiki I; Johnson DH
    J Clin Oncol; 2006 Oct; 24(30):4798-800. PubMed ID: 17050864
    [No Abstract]   [Full Text] [Related]  

  • 31. A further piece of the puzzle: positive FOBT, colonoscopy, aspirin and the prevention of colorectal cancer.
    Ockenga J
    Digestion; 2012; 85(4):276-7. PubMed ID: 22538259
    [No Abstract]   [Full Text] [Related]  

  • 32. Digging for data from the COX-2 trials.
    McCormack JP; Rangno R
    CMAJ; 2002 Jun; 166(13):1649-50. PubMed ID: 12126315
    [No Abstract]   [Full Text] [Related]  

  • 33. Asthmatic reaction induced by celecoxib in a patient with aspirin-induced asthma.
    Muñoz-Cano R; Bartra J; Vennera MC; Valero A; Picado C
    J Investig Allergol Clin Immunol; 2009; 19(1):75-6. PubMed ID: 19274941
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
    Sooriakumaran P; Coley HM; Fox SB; Macanas-Pirard P; Lovell DP; Henderson A; Eden CG; Miller PD; Langley SE; Laing RW
    Anticancer Res; 2009 May; 29(5):1483-8. PubMed ID: 19443354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials. Nail-biting time for trials of COX-2 drugs.
    Couzin J
    Science; 2004 Dec; 306(5702):1673-5. PubMed ID: 15576585
    [No Abstract]   [Full Text] [Related]  

  • 36. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
    Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
    Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
    Sinsakul M; Sika M; Rodby R; Middleton J; Shyr Y; Chen H; Han E; Lehrich R; Clyne S; Schulman G; Harris R; Lewis J
    Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevention of post-surgical neuralgia.
    Reuben SS
    Pain; 2005 Jan; 113(1-2):242-3; author reply 243-4. PubMed ID: 15621388
    [No Abstract]   [Full Text] [Related]  

  • 40. The pain game.
    Wadman M
    Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.